DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Hypnotherapy in Treating Chronic Pain in Cancer Survivors

Not Applicable

Completed

Conditions: Anxiety
Cancer Survivor
Depression
Chronic Pain
Sleep Disorder

Interventions: Other: Questionnaire Administration
Procedure: Hypnotherapy

First Posted Date: 2015-12-22

Last Posted Date: 2017-08-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 39

Registration Number: NCT02637297

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Plasma Cell Myeloma
Transplant-Related Carcinoma

Interventions: Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide

First Posted Date: 2015-12-02

Last Posted Date: 2025-02-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT02619682

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Phase 1

Terminated

Conditions: Stage IV Merkel Cell Carcinoma AJCC v7
Merkel Cell Polyomavirus Infection

Interventions: Drug: Avelumab
Other: Laboratory Biomarker Analysis
Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
Radiation: Radiation Therapy
Biological: Recombinant Interferon Beta

First Posted Date: 2015-10-23

Last Posted Date: 2022-03-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 8

Registration Number: NCT02584829

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

HSV529 Vaccine in HSV-2 Seropositive Adults

Phase 1

Completed

Conditions: Herpes Simplex Virus 2

Interventions: Biological: HSV529
Drug: Valacyclovir

First Posted Date: 2015-10-08

Last Posted Date: 2019-01-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 10

Registration Number: NCT02571166

Locations: 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States

Meals and Grazing Study

Not Applicable

Completed

Conditions: Healthy

Interventions: Behavioral: High Eating Frequency (High EF)
Behavioral: Low Eating Frequency (Low EF)

First Posted Date: 2015-09-14

Last Posted Date: 2015-09-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT02548026

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Diet and Metabolic Inflammation

Not Applicable

Completed

Conditions: Diabetes
Inflammation
Insulin Resistance
Obesity
Cancer

Interventions: Other: Diet B
Other: Diet A

First Posted Date: 2015-09-03

Last Posted Date: 2016-10-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT02539355

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Carcinoma
Cancer Survivor

Interventions: Other: Informational Intervention
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Support Group Therapy

First Posted Date: 2015-08-13

Last Posted Date: 2018-10-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 10

Registration Number: NCT02521961

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

The Vaginal Health Trial

Phase 3

Completed

Conditions: Menopause
Atrophy of Vagina
Dyspareunia (Female)

Interventions: Device: Replens
Drug: Vagifem
Other: Placebo gel
Other: Placebo tablet

First Posted Date: 2015-08-05

Last Posted Date: 2018-07-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 302

Registration Number: NCT02516202

Locations: 🇺🇸
Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

Phase 2

Completed

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2015-07-31

Last Posted Date: 2019-02-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT02513498

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

and more 3 locations

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

Phase 2

Completed

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Carfilzomib
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2015-07-08

Last Posted Date: 2019-02-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT02491359

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy